newsfilter
← Latest News
Business Wire·

MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results

– Phase 3 MANIFEST-2 topline results expected by the end of November, with detailed findings in oral presentation at ASH 2023 – Monjuvi® U.S. net product sales of US$ 23.4 million (€ 21.5 million) for the third